Ton Wang1, Nicholas Osborne1, John Rechtenwald2, Alex Kim1, Niki Matusko1, Rita Mayle1, Mark S Cohen3. 1. University of Michigan, Department of Surgery, Ann Arbor, MI, USA. 2. University of Wisconsin, Department of Surgery, Madison, WI, USA. 3. University of Michigan, Department of Surgery, Ann Arbor, MI, USA; University of Michigan, Department of Pharmacology, Ann Arbor, MI, USA. Electronic address: cohenmar@med.umich.edu.
Abstract
BACKGROUND: In-transit metastatic melanoma of the extremity is a clinically aggressive disease. For patients with disease confined to the limb, regional chemotherapy remains an effective option. However, no studies thus far have included cytoreduction or perfusion/infusion without using a limb tourniquet as part of the operative procedure. We hypothesize that combining cytoreduction with no-tourniquet HILP/HILI is safe in patients of all ages and results in durable responses. METHODS: A retrospective analysis was performed of a prospectively collected database of patients with in-transit malignant melanoma who underwent cytoreduction and HILP/HILI between 2013 and 2017. The primary endpoint was RECIST response at 3-12 months. Secondary endpoints included length of hospital stay, adverse effects, overall survival, and time to recurrence. A subgroup analysis was performed in patients ≥80 years old. RESULTS: HILP patients had significantly higher disease burdens than HILI patients. Complete response rates for HILP and HILI were 95% and 75%, respectively at 3 months and 47% and 50%, respectively at 1 year (50% for patients >80) with 100% 1-year survival rates for both HILP and HILI patients. Three-year survival rates were 57% (HILP), 52% (HILI) and 68% (patients >80 years old). The average length of stay for all patients was 3.6 ± 1.4 days. CONCLUSION: Combining cytoreduction with no-tourniquet HILP/HILI for in-transit metastatic melanoma of the extremity resulted in 100% survival regardless of age at 1 year and 68% 3-year survival in patients over 80 without any increase in adverse events.
BACKGROUND: In-transit metastatic melanoma of the extremity is a clinically aggressive disease. For patients with disease confined to the limb, regional chemotherapy remains an effective option. However, no studies thus far have included cytoreduction or perfusion/infusion without using a limb tourniquet as part of the operative procedure. We hypothesize that combining cytoreduction with no-tourniquet HILP/HILI is safe in patients of all ages and results in durable responses. METHODS: A retrospective analysis was performed of a prospectively collected database of patients with in-transit malignant melanoma who underwent cytoreduction and HILP/HILI between 2013 and 2017. The primary endpoint was RECIST response at 3-12 months. Secondary endpoints included length of hospital stay, adverse effects, overall survival, and time to recurrence. A subgroup analysis was performed in patients ≥80 years old. RESULTS: HILP patients had significantly higher disease burdens than HILI patients. Complete response rates for HILP and HILI were 95% and 75%, respectively at 3 months and 47% and 50%, respectively at 1 year (50% for patients >80) with 100% 1-year survival rates for both HILP and HILI patients. Three-year survival rates were 57% (HILP), 52% (HILI) and 68% (patients >80 years old). The average length of stay for all patients was 3.6 ± 1.4 days. CONCLUSION: Combining cytoreduction with no-tourniquet HILP/HILI for in-transit metastatic melanoma of the extremity resulted in 100% survival regardless of age at 1 year and 68% 3-year survival in patients over 80 without any increase in adverse events.
Authors: Wendy R Cornett; Linda M McCall; Rebecca P Petersen; Merrick I Ross; Henry A Briele; R Dirk Noyes; Jeffrey J Sussman; William G Kraybill; John M Kane; H Richard Alexander; Jeffrey E Lee; Paul F Mansfield; James F Pingpank; David J Winchester; Richard L White; Vijaya Chadaram; James E Herndon; Douglas L Fraker; Douglas S Tyler Journal: J Clin Oncol Date: 2006-09-01 Impact factor: 44.544
Authors: Rebecca L Read; Lauren Haydu; Robyn P M Saw; Michael J Quinn; Kerwin Shannon; Andrew J Spillane; Jonathan R Stretch; Richard A Scolyer; John F Thompson Journal: Ann Surg Oncol Date: 2014-09-26 Impact factor: 5.344
Authors: Timothy M Pawlik; Merrick I Ross; Marcella M Johnson; Christopher W Schacherer; Dana M McClain; Paul F Mansfield; Jeffrey E Lee; Janice N Cormier; Jeffrey E Gershenwald Journal: Ann Surg Oncol Date: 2005-06-16 Impact factor: 5.344
Authors: Dirk J Grünhagen; Flavia Brunstein; Wilfried J Graveland; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont Journal: Ann Surg Date: 2004-12 Impact factor: 12.969
Authors: Junko Johansson; Roberta Kiffin; Annica Andersson; Per Lindnér; Peter L Naredi; Roger Olofsson Bagge; Anna Martner Journal: Front Oncol Date: 2018-12-03 Impact factor: 6.244